Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 91, Issue 3, 2011, Pages 142-152

  Colvin, Lyn ^a,b   Slack Smith, Linda ^b   Stanley, Fiona J ^a   Bower, Carol ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Western Australian Birth Defects Registry   (Australia)

Author keywords

Antidepressant; Birth defect; Data linkage; Pharmacoepidemiology; Pharmacovigilance

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; SERTRALINE;

ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CHILD; DRUG SAFETY; ECTOPIC PREGNANCY; FEMALE; FIRST TRIMESTER PREGNANCY; GENETIC LINKAGE; GESTATIONAL AGE; HUMAN; LOW BIRTH WEIGHT; PARITY; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREMATURITY; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; VESICOURETERAL REFLUX;

ABORTION, EUGENIC; ADVERSE DRUG REACTION REPORTING SYSTEMS; AUSTRALIA; DEPRESSIVE DISORDER; FEMALE; HUMANS; INFANT, NEWBORN; MOOD DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREGNANCY, ECTOPIC; REGISTRIES; SEROTONIN UPTAKE INHIBITORS;

EID: 79952610115     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20773     Document Type: Article

References (80)

1. ACOG Committee on Practice Bulletins-Obstetrics. American College ofObstetricians and Gynecologists. 2008. Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 111: 1001-1020.
2. Andrews EB, Tennis P. 2007. Promise and pitfalls of administrative data in evaluating pregnancy outcomes. Pharmacoepidemiol Drug Saf 16: 1181-1183.
3. Australian Bureau of Statistics. 2006. Australian Historical Population Statistics, 2006. Commonwealth of Australia, Canberra. Report nr 3105.0.65.001. Available from:.
4. Australian Bureau of Statistics. 2008. Socio-Economic Indexes for Areas (SEIFA) - Technical Paper 2006. Commonwealth of Australia, Canberra. Report nr 2039.0.55.001.
5. Australian Drug Evaluation Committee. 1999. Prescribing medicines in pregnancy: an Australian categorisation of risk of drug use in pregnancy. 4th ed.: Therapeutic Drugs Administration.
6. Australian Government Department of Health and Ageing. 2008. Schedule of Pharmaceutical Benefits.
7. Australian Institute of Health and Welfare. 2006. Australia's Health 2006. Canberra: AIHW. Report nr AIHW Cat. No. AUS 73. Available from:.
8. Bakker MK, De Walle HE, Wilffert B, de Jong-Van den Berg LT. 2010. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiol Drug Saf 19: 808-813.
9. Bérard A, Ramos E, Rey E, et al. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80: 18-27.
10. Blair E, Liu Y, Cosgrove P. 2004. Choosing the best estimate of gestational age from routinely collected population-based perinatal data. Paediatr Perinat Epidemiol 18: 270-276.
11. Blair EM, Liu Y, de Klerk NH, Lawrence DM. 2005. Optimal fetal growth for the Caucasian singleton and assessment of appropriateness of fetal growth: an analysis of a total population perinatal database. BMC Pediatr 5: 13.
12. Bonari L, Pinto N, Ahn E, et al. 2004. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 49: 726-735.
13. Bower C, Ramsay JM. 1994. Congenital heart disease: a 10 year cohort. J Paediatr Child Health 30: 414-418.
14. Bower C, Rudy E, Callaghan A, et al. 2009. Report of the Birth Defects Registry of Western Australia, 1980-2008. Subiaco: King Edward Memorial Hospital, Women and Newborn Health Service. Report nr 16. Available from: .
15. Bower C, Rudy E, Callaghan A, et al. 2010. Age at diagnosis of birth defects. Birth Defects Res A Clin Mol Teratol 88: 251-255.
16. Bower C, Silva D, Henderson TR, et al. 2000. Ascertainment of birth defects: the effect on completeness of adding a new source of data. J Paediatr Child Health 36: 574-576.
17. Bower C, Stanley FJ. 1983. Western Australian Congenital Malformations Register. Med J Aust 2: 189-191.
18. Brameld KJ, Holman CD, Bass AJ, et al. 1998. Hospitalisation of the elderly during the last year of life: an application of record linkage in Western Australia 1985-1994. J Epidemiol Community Health 52: 740-744.
19. British Paediatric Association. 1979. Classification of Diseases. Codes designed for use in the classification of paediatric and perinatal disorders. (Successor to the Cardiff Diagnostic Classification.) A paediatric supplement compatible with WHO International Classification of Diseases, 1977. London: BPA. p 314.
20. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354: 579-587.
21. Chambers CD, Johnson KA, Dick LM, et al. 1996. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 335: 1010-1015.
22. Cohen LS, Altshuler LL, Harlow BL, et al. 2006. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295: 499-507.
23. Colvin L, Payne J, Parsons D, Bower C. 2007. Alcohol consumption during pregnancy in nonindigenous west Australian women. Alcohol Clin Exp Res 31: 276-284.
24. Colvin L, Slack-Smith L, Stanley FJ, Bower C. 2009. Pharmacovigilance in pregnancy using population-based linked datasets. Pharmacoepidemiol Drug Saf 18: 211-225.
25. Colvin L, Slack-Smith L, Stanley FJ, et al. 2010. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 19: 1137-1150.
26. Diav-Citrin O, Shechtman S, Weinbaum D, et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 66: 695-705.
27. Duke JM, Sibbritt DW, Young AF. 2007. Is there an association between the use of oral contraception and depressive symptoms in young Australian women? Contraception 75: 27-31.
28. Ehrenstein V, Sørensen HT, Bakketeig LS, Pedersen L. 2010. Medical databases in studies of drug teratogenicity: methodological issues. Clin Epidemiol 2: 37-43.
29. Emory EK, Dieter JN. 2006. Maternal depression and psychotropic medication effects on the human fetus. Ann N Y Acad Sci 1094: 287-291.
30. Ericson A, Källén B, Wiholm B. 1999. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 55: 503-508.
31. Field T. 1995. Infants of depressed mothers. Infant Behavior and Development 18: 1-13.
32. Field T. 2010. Prenatal depression and selective serotonin reuptake inhibitors. Int J Neurosci 120: 163-167.
33. Freemantle CJ, Read AW, de Klerk NH, et al. 2006. Patterns, trends, and increasing disparities in mortality for Aboriginal and non-Aboriginal infants born in Western Australia, 1980-2001: population database study. Lancet 367: 1758-1766.
34. García Rodríguez LA, Pérez Gutthann S. 1998. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45: 419-425.
35. Garland M. 1998. Pharmacology of drug transfer across the placenta. Obstet Gynecol Clin North Am 25: 21-42.
36. Gavin AR, Holzman C, Siefert K, Tian Y. 2009. Maternal depressive symptoms, depression, and psychiatric medication use in relation to risk of preterm delivery. Womens Health Issues 19: 325-334.
37. Gaynes BN, Gavin N, Meltzer-Brody S, et al. 2005. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ) 119: 1-8.
38. Giles GG. 2005. Medical record linkage in Australia: this is as good as it gets. ANZ J Surg 75: 259.
39. Gladstone J, Levy M, Nulman I, Koren G. 1997. Characteristics of pregnant women who engage in binge alcohol consumption. CMAJ 156: 789-794.
40. Hendrick V, Smith LM, Suri R, et al. 2003a. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 188: 812-815.
41. Hendrick V, Stowe ZN, Altshuler LL, et al. 2003b. Placental passage of antidepressant medications. Am J Psychiatry 160: 993-996.
42. Holman CD, Bass AJ, Rosman DL, et al. 2008. A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. Aust Health Rev 32: 766-777.
43. Holman CD, Bass AJ, Rouse IL, Hobbs MS. 1999. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 23: 453-459.
44. Jones NA, Field T, Fox NA, et al. 1998. Newborns of mothers with depressive symptoms are physiologically less developed. Infant Behav Dev 21: 537-541.
45. Källén BA, Otterblad Olausson P. 2007. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79: 301-308.
46. Kelman CW, Pearson SA, Day RO, et al. 2007. Evaluating medicines: let's use all the evidence. Med J Aust 186: 249-252.
47. Kornum JB, Nielsen RB, Pedersen L, et al. 2010. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2: 29-36.
48. Kulin NA, Pastuszak A, Sage SR, et al. 1998. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 279: 609-610.
49. Kurki T, Hiilesmaa V, Raitasalo R, et al. 2000. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 95: 487-490.
50. Ligi I, Grandvuillemin I, Andres V, et al. 2010. Low birth weight infants and the developmental programming of hypertension: a focus on vascular factors. Semin Perinatol 34: 188-192.
51. Louik C, Lin AE, Werler MM, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356: 2675-2683.
52. Marcus SM, Flynn HA. 2008. Depression, antidepressant medication, and functioning outcomes among pregnant women. Int J Gynecol Obstet 100: 248-251.
53. McGrath C, Buist A, Norman TR. 1999. Treatment of anxiety during pregnancy: effects of psychotropic drug treatment on the developing fetus. Drug Saf 20: 171-186.
54. Milne E, Laurvick CL, Blair E, et al. 2007. Fetal growth and acute childhood leukemia: looking beyond birth weight. Am J Epidemiol 166: 151-159.
55. Mitchell AA. 2005. Studies of drug-induced birth defects. In: Strom B, editor. Pharmacoepidemiology.Fourth ed. West Sussex: Wiley & Sons. pp 501-514.
56. Nakhai-Pour HR, Broy P, Bérard A. 2010. Use of antidepressants during pregnancy and the risk of spontaneous abortion. CMAJ 182: 1031-1037.
57. Norman M. 2010. Preterm birth-an emerging risk factor for adult hypertension? Semin Perinatol 34: 183-187.
58. Oberlander TF, Papsdorf M, Brain UM, et al. 2010. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med 164: 444-451.
59. Oberlander TF, Warburton W, Misri S, et al. 2006. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63: 898-906.
60. Pastuszak A, Schick-Boschetto B, Zuber C, et al. 1993. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 269: 2246-2248.
61. Pedersen LH, Henriksen TB, Vestergaard M, et al. 2009. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339: b3569.
62. Platt R, Madre L, Reynolds R, Tilson H. 2008. Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf 17: 1175-1182.
63. Ramos E, Oraichi D, Rey B et al. 2007. Prevalence and predictors of antidepressant use in a cohort of pregnant women. BJOG 114: 1055-1064.
64. Rampono J, Simmer K, Ilett KF, et al. 2009. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42: 95-100.
65. Reis M, Källén B. 2010. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 40: 1723-1733.
66. Simon GE, Cunningham ML, Davis RL. 2002. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 159: 2055-2061.
67. Sivojelezova A, Shuhaiber S, Sarkissian L, et al. 2005. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 193: 2004-2009.
68. Stanley FJ, Croft ML, Gibbins J, Read AW. 1994. A population database for maternal and child health research in Western Australia using record linkage. Paediatr Perinat Epidemiol 8: 433-447.
69. Suri R, Altshuler L, Hellemann G, et al. 2007. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 164: 1206-1213.
70. Syme MR, Paxton JW, Keelan JA. 2004. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43: 487-514.
71. Therapeutic Goods Administration. 2005. Advice for women taking paroxetine intending to become pregnant or in early pregnancy. Australian Government Department of Health and Ageing.
72. Toh S, Mitchell AA, Louik C, et al. 2009. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 29: 555-560.
73. Ververs T, Kaasenbrood H, Visser G, et al. 2006. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 62: 863-870.
74. Ververs T, van Dijk L, Yousofi S, et al. 2009. Depression during pregnancy: views on antidepressant use and information sources of general practitioners and pharmacists. BMC Health Serv Res 9: 119.
75. Wen SW, Yang Q, Garner P, et al. 2006. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 194: 961-966.
76. Williams K, Leonard H, Tursan d'Espaignet E, et al. 2005. Hospitalisations from birth to 5 years in a population cohort of Western Australian children with intellectual disability. Arch Dis Child 90: 1243-1248.
77. Wisner KL. 2010. SSRI treatment during pregnancy: are we asking the right questions? Depress Anxiety 27: 695-698.
78. Wisner KL, Sit DK, Hanusa BH, et al. 2009. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 166: 557-566.
79. Wogelius P, Nørgaard M, Gislum M, et al. 2006. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17: 701-704.
80. Yonkers KA, Wisner KL, Stewart DE, et al. 2009. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 31: 403-413.